RxDoctor Payments Data

Carly Prudic

Family · Durango, CONPI 1306498860

Payments from drug & device makers

$1,805in general payments, 2019–2025

Across 65 payments — averaging $27.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$482
  • Boston Scientific$188
  • Neurocrine Biosciences, Inc.$108
  • Nevro Corp.$106
  • UCB, Inc.$99
  • Novartis$82
  • plus $742 from 19 others

What the payments were for

  • Food & beverage$1,805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,805 in reported general payments places this provider in the 85th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$78,769
Medicare patients
191
Services billed
7,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant70$116,385
Nurtec OdtRimegepant Sulfate49$52,148
Ajovy AutoinjectorFremanezumab-Vfrm40$40,989
Emgality PenGalcanezumab-Gnlm32$28,847
Aimovig AutoinjectorErenumab-Aooe28$28,528
JardianceEmpagliflozin13$21,081
QuliptaAtogepant13$18,216
EliquisApixaban15$13,226
Albuterol Sulfate HfaAlbuterol Sulfate26$791
Levothyroxine Sodium57$608
Montelukast Sodium29$499
Gabapentin55$496
Atorvastatin Calcium52$442
Tamsulosin Hcl19$370
Donepezil Hcl39$366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$482$134,60183 claims
PfizerNurtec Odt, Eliquis$66$65,37364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,182 family providers in Colorado.

Other family in Durango

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →